Literature DB >> 29190263

Scale-Up of Voluntary Medical Male Circumcision Services for HIV Prevention - 12 Countries in Southern and Eastern Africa, 2013-2016.

Jonas Z Hines, Onkemetse Conrad Ntsuape, Kananga Malaba, Tiruneh Zegeye, Kennedy Serrem, Elijah Odoyo-June, Rose Kolola Nyirenda, Wezi Msungama, Kondwani Nkanaunena, Jotamo Come, Marcos Canda, Herminio Nhaguiombe, Ella K Shihepo, Brigitte L T Zemburuka, Gram Mutandi, Emmanuel Yoboka, André H Mbayiha, Hilda Maringa, Alfred Bere, J Joseph Lawrence, Gissenge J I Lija, Daimon Simbeye, Kokuhumbya Kazaura, Ramadhani S Mwiru, Stella Alamo Talisuna, Joseph Lubwama, Geoffrey Kabuye, James Exnobert Zulu, Omega Chituwo, Maybin Mumba, Sinokuthemba Xaba, John Mandisarisa, Brittney N Baack, Lawrence Hinkle, Jonathan M Grund, Stephanie M Davis, Carlos Toledo.   

Abstract

Countries in Southern and Eastern Africa have the highest prevalence of human immunodeficiency virus (HIV) infection in the world; in 2015, 52% (approximately 19 million) of all persons living with HIV infection resided in these two regions.* Voluntary medical male circumcision (VMMC) reduces the risk for heterosexually acquired HIV infection among males by approximately 60% (1). As such, it is an essential component of the Joint United Nations Programme on HIV/AIDS (UNAIDS) strategy for ending acquired immunodeficiency syndrome (AIDS) by 2030 (2). Substantial progress toward achieving VMMC targets has been made in the 10 years since the World Health Organization (WHO) and UNAIDS recommended scale-up of VMMC for HIV prevention in 14 Southern and Eastern African countries with generalized HIV epidemics and low male circumcision prevalence (3).† This has been enabled in part by nearly $2 billion in cumulative funding through the President's Emergency Plan for AIDS Relief (PEPFAR), administered through multiple U.S. governmental agencies, including CDC, which has supported nearly half of all PEPFAR-supported VMMCs to date. Approximately 14.5 million VMMCs were performed globally during 2008-2016, which represented 70% of the original target of 20.8 million VMMCs in males aged 15-49 years through 2016 (4). Despite falling short of the target, these VMMCs are projected to avert 500,000 HIV infections by the end of 2030 (4). However, UNAIDS has estimated an additional 27 million VMMCs need to be performed by 2021 to meet the Fast Track targets (2). This report updates a previous report covering the period 2010-2012, when VMMC implementing partners supported by CDC performed approximately 1 million VMMCs in nine countries (5). During 2013-2016, these implementing partners performed nearly 5 million VMMCs in 12 countries. Meeting the global target will require redoubling current efforts and introducing novel strategies that increase demand among subgroups of males who have historically been reluctant to undergo VMMC.

Entities:  

Mesh:

Year:  2017        PMID: 29190263      PMCID: PMC5708689          DOI: 10.15585/mmwr.mm6647a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Countries in Southern and Eastern Africa have the highest prevalence of human immunodeficiency virus (HIV) infection in the world; in 2015, 52% (approximately 19 million) of all persons living with HIV infection resided in these two regions.* Voluntary medical male circumcision (VMMC) reduces the risk for heterosexually acquired HIV infection among males by approximately 60% (). As such, it is an essential component of the Joint United Nations Programme on HIV/AIDS (UNAIDS) strategy for ending acquired immunodeficiency syndrome (AIDS) by 2030 (). Substantial progress toward achieving VMMC targets has been made in the 10 years since the World Health Organization (WHO) and UNAIDS recommended scale-up of VMMC for HIV prevention in 14 Southern and Eastern African countries with generalized HIV epidemics and low male circumcision prevalence (). This has been enabled in part by nearly $2 billion in cumulative funding through the President’s Emergency Plan for AIDS Relief (PEPFAR), administered through multiple U.S. governmental agencies, including CDC, which has supported nearly half of all PEPFAR-supported VMMCs to date. Approximately 14.5 million VMMCs were performed globally during 2008–2016, which represented 70% of the original target of 20.8 million VMMCs in males aged 15–49 years through 2016 (). Despite falling short of the target, these VMMCs are projected to avert 500,000 HIV infections by the end of 2030 (). However, UNAIDS has estimated an additional 27 million VMMCs need to be performed by 2021 to meet the Fast Track targets (). This report updates a previous report covering the period 2010–2012, when VMMC implementing partners supported by CDC performed approximately 1 million VMMCs in nine countries (). During 2013–2016, these implementing partners performed nearly 5 million VMMCs in 12 countries. Meeting the global target will require redoubling current efforts and introducing novel strategies that increase demand among subgroups of males who have historically been reluctant to undergo VMMC. CDC supports national ministries of health to provide VMMC services for HIV prevention in 12 priority countries: Botswana, Ethiopia, Kenya, Malawi, Mozambique, Namibia, Rwanda, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe. The VMMC service package includes male circumcision, offer of HIV testing services and linkage to care and treatment for men testing HIV positive, HIV risk reduction education, condom provision, and screening and treatment or referral for sexually transmitted infections (). Circumcisions are performed under local anesthesia by trained clinicians (clinical officers and nurses in most countries). All VMMC clients provide informed consent; consenting for minors adheres to national standards. CDC-supported VMMC programs reported program data on key indicators. Data were reported in accordance with the fiscal year October 1–September 30. Data were drawn from site-level VMMC client registers, collected by VMMC implementing partners, and reported to PEPFAR and CDC. The primary indicator was the total number of VMMCs performed; disaggregated indicators included VMMC method (conventional surgical circumcision or device-based circumcision), client age group, HIV test results among VMMC clients tested at VMMC sites, and attendance at postoperative follow-up visits within 14 days. During 2013–2014, client age was reported as <15 or ≥15 years; during 2015–2016, age was categorized as <15 years, 15–29 years, and ≥30 years. HIV prevalence was calculated by dividing the number of males that tested positive for HIV infection by the number undergoing HIV testing services at VMMC sites. In this report, disaggregated indicators were excluded from multi-country analyses if the sum of values in the disaggregated indicator was <85% or >100% of the total number of VMMCs reported for a given year. During 2013–2016, CDC supported 4,859,948 VMMCs in 12 Southern and Eastern African countries (Table 1). The annual number of VMMCs increased during 2013–2015. In 2016, 181,737 (13.4%) fewer VMMCs were performed than in 2015. In multi-country analyses, the proportion of VMMC clients aged <15 years increased each year during 2013–2016, from 31.7% in 2013 to 47.6% in 2016 (Table 2). Conversely, the proportion of VMMC clients aged 15–29 years declined from 48.4% in 2015 to 45.6% in 2016. During 2013–2016, circumcision devices were used in 42,520 (1.1%) of the VMMCs.
TABLE 1

VMMCs provided in CDC-supported VMMC programs — 12 Southern and Eastern African countries, 2013–2016

CountryFiscal year*
Total
2013201420152016
Botswana
11,855
12,745
7,320
23,977
55,897
Ethiopia
14,037
10,439
9,861
10,655
44,992
Kenya
144,943
154,776
147,998
176,056
623,773
Malawi
18,398
18,889
18,910
19,180
75,377
Mozambique
121,369
141,113
159,299
184,488
606,269
Namibia
0
685
7,132
10,194
18,011
Rwanda
0
21,475
25,000
8,809
55,284
South Africa
139,174
185,193
193,311
149,081
666,759
Tanzania
159,230
278,948
341,544
181,199
960,921
Uganda
272,182
329,059
251,815
225,597
1,078,653
Zambia
96,183
154,941
147,962
126,765
525,851
Zimbabwe
6,171
39,840
44,868
57,282
148,161
Yearly total
983,542
1,348,103
1,355,020
1,173,283
4,859,948
Cumulative total 983,542 2,331,645 3,686,665 4,859,948

Abbreviation: VMMC = voluntary medical male circumcision.

* October 1–September 30.

TABLE 2

Disaggregated indicators for CDC-supported VMMC programs — 12 Southern and Eastern African countries, 2013–2016

CountryFiscal year*No. of CDC-supported VMMCs performedNo. of clients aged <15 yrs (%)No. of clients aged 15–29 yrs (%)No. of clients aged ≥30 yrs (%)No. of VMMCs performed using devices (%)No. of VMMC clients receiving HIV testing services (%)§No. of clients testing HIV positive (%)No. of clients with postoperative follow-up within 14 days of VMMC (%)
Botswana
2013
11,855
4,432 (37.4)
NR (—)**
NR (—)**
807 (6.8)
11,855 (100.0)
23 (0.2)
9,880 (83.3)
2014
12,745
8,765 (68.8)
NR (—)**
NR (—)**
64 (0.5)
12,711 (99.7)
136 (1.1)
4,572 (35.9)**
2015
7,320
4,759 (65.0)
2,040 (27.9)
521 (7.1)
1,896 (25.9)
5,368 (73.3)
134 (2.5)
4,619 (63.1)
2016
23,977
4,249 (17.7)**
3,660 (15.3)**
1,414 (5.9)**
2,715 (11.3)**
6,216 (25.9)**
271 (4.4)**
5,562 (23.2)**
Total
55,897
22,205 (39.7)
5,700 (10.2)
1,935 (3.5)
5,482 (9.8)
36,150 (64.7)
564 (1.6)
24,633 (44.1)
Ethiopia
2013
14,037
56 (0.4)
11,572 (82.4)
2,409 (17.2)
0 (0.0)
13,268 (94.5)
37 (0.3)
13,905 (99.1)
2014
10,439
1,671 (16.0)
6,880 (65.9)
1,888 (18.1)
0 (0.0)
5,802 (55.6)
4 (0.1)
10,402 (99.6)
2015
9,861
608 (6.2)
7,339 (74.4)
1,914 (19.4)
0 (0.0)
8,081 (81.9)
9 (0.1)
9,861 (100.0)
2016
10,655
3,194 (30.0)
6,143 (57.7)
1,318 (12.4)
0 (0.0)
4,664 (43.8)
5 (0.1)
10,597 (99.5)
Total
44,992
5,529 (12.3)
31,934 (71.0)
7,529 (16.7)
0 (0.0)
31,815 (70.7)
55 (0.2)
44,765 (99.5)
Kenya
2013
144,943
52,643 (36.3)
NR (—)**
NR (—)**
512 (0.4)
112,657 (77.7)
1,360 (1.2)
45,300 (31.3)**
2014
154,776
87,066 (56.3)
NR (—)**
NR (—)**
302 (0.2)
129,530 (83.7)
1,380 (1.1)
66,634 (43.1)
2015
147,998
94,634 (63.9)
48,735 (32.9)
4,544 (3.1)
448 (0.3)
133,584 (90.3)
1,797 (1.3)
89,724 (60.6)
2016
176,056
123,006 (69.9)
49,075 (27.9)
3,976 (2.3)
2,201 (1.3)
145,931 (82.9)
575 (0.4)
116,933 (66.4)
Total
623,773
357,349 (57.3)
97,810 (15.7)
8,520 (1.4)
3,463 (0.6)
521,702 (83.6)
5,112 (1.0)
318,591 (51.1)
Malawi
2013
18,398
4,749 (25.8)
NR (—)**
NR (—)**
0 (0.0)
18,354 (99.8)
262 (1.4)
13,287 (72.2)
2014
18,889
8,594 (45.5)
NR (—)**
NR (—)**
299 (1.6)
18,867 (99.9)
132 (0.7)
15,099 (79.9)
2015
18,910
6,928 (36.6)
10,033 (53.1)
1,949 (10.3)
2,949 (15.6)
18,871 (99.8)
427 (2.3)
11,309 (59.8)
2016
19,180
9,127 (47.6)
9,022 (47.0)
1,031 (5.4)
0 (0.0)
19,022 (99.2)
125 (0.7)
14,956 (78.0)
Total
75,377
29,398 (39.0)
19,055 (25.3)
2,980 (4.0)
3,248 (4.3)
75,114 (99.7)
946 (1.3)
54,651 (72.5)
Mozambique
2013
121,369
62,136 (51.2)
NR (—)**
NR (—)**
0 (0.0)
123,909 (102.1)**
2,944 (2.4)**
NR (—)**
2014
141,113
75,469 (53.5)
NR (—)**
NR (—)**
0 (0.0)
143,055 (101.4)**
1,475 (1.0)**
98,458 (69.8)
2015
159,299
78,863 (49.5)
72,405 (45.5)
8,031 (5.0)
0 (0.0)
156,308 (98.1)
1,844 (1.2)
110,111 (69.1)
2016
184,488
78,117 (42.3)
95,033 (51.5)
11,338 (6.1)
0 (0.0)
172,814 (93.7)
2,473 (1.4)
133,781 (72.5)**
Total
606,269
294,585 (48.6)
167,438 (27.6)
19,369 (3.2)
0 (0.0)
596,086 (98.3)
8,736 (1.5)
342,350 (70.6)
Namibia
2013
0
NA
NA
NA
NA
NA
NA
NA
2014
685
72 (10.5)
597 (87.2)
16 (2.3)
0 (0.0)
685 (100.0)
6 (0.9)
562 (82.0)
2015
7,132
15 (0.2)
5,706 (80.0)
1,411 (19.8)
0 (0.0)
6,283 (88.1)
211 (3.4)
7,132 (100.0)
2016
10,194
1 (0.0)
8,319 (81.6)
1,874 (18.4)
0 (0.0)
8,686 (85.2)
183 (2.1)
10,157 (99.6)
Total
18,011
88 (0.5)
14,622 (81.2)
3,301 (18.3)
0 (0.0)
15,654 (86.9)
400 (2.6)
17,851 (99.1)
Rwanda
2013
0
NA
NA
NA
NA
NA
NA
NA
2014
21,475
NR (—)**
NR (—)**
NR (—)**
0 (0.0)
17,777 (82.8)
10 (0.1)
NR (—)**
2015
25,000
4,693 (18.8)
17,050 (68.2)
3,227 (12.9)
194 (0.8)
24,970 (99.9)
15 (0.1)
16,647 (66.6)**
2016
8,809
593 (6.7)
7,255 (82.4)
961 (10.9)
1,336 (15.2)
8,809 (100.0)
9 (0.1)
7,454 (84.6)**
Total
55,284
5,286 (9.6)
24,305 (44.0)
4,188 (7.6)
1,530 (3.7)
51,556 (93.3)
34 (0.1)
24,101 (71.3)
South Africa
2013
139,174
29,889 (21.5)
NR (—)**
NR (—)**
0 (0.0)
142,390 (102.3)**
4,048 (2.8)**
66,667 (47.9)
2014
185,193
68,231 (36.8)
NR (—)**
NR (—)**
56 (0.0)
194,746 (105.2)**
4,724 (2.4)**
93,939 (50.7)
2015
193,311
84,239 (43.6)
NR (—)**
NR (—)**
976 (0.5)
187,859 (97.2)
5,702 (3.0)
93,047 (48.1)
2016
149,081
69,266 (46.5)
NR (—)**
NR (—)**
3,903 (2.6)
150,211 (100.8)**
6,072 (4.0)**
102,021 (68.4)
Total
666,759
251,625 (37.7)
NR (—)
NR (—)
4,935 (0.7)
675,206 (101.3)
20,546 (3.0)
355,674 (53.3)
Tanzania
2013
159,230
64,173 (40.3)
NR (—)**
NR (—)**
0 (0.0)
NR (—)**
NR (—)**
NR (—)**
2014
278,948
113,731 (40.8)
NR (—)**
NR (—)**
0 (0.0)
213,239 (76.4)
1,029 (0.5)
NR (—)**
2015
341,544
142,740 (41.8)
172,594 (50.5)
26,210 (7.7)
0 (0.0)
335,105 (98.1)
926 (0.3)
312,691 (91.6)
2016
181,199
88,607 (48.9)
79,239 (43.7)
13,353 (7.4)
0 (0.0)
180,845 (99.8)
458 (0.3)
150,605 (83.1)
Total
960,921
409,251 (42.6)
251,833 (26.2)
39,563 (4.1)
0 (0.0)
729,189 (75.9)
2,413 (0.3)
463,296 (88.6)
Uganda
2013
272,182
54,608 (20.1)
NR (—)**
NR (—)**
NR (—)**
237,830 (87.4)
NR (—)**
NR (—)**
2014
329,059
112,555 (34.2)
NR (—)**
NR (—)**
NR (—)**
298,060 (90.6)
NR (—)**
NR (—)**
2015
251,815
0 (0.0)**
0 (0.0)**
466 (0.2)**
990 (0.4)**
112,465 (44.7)**
920 (0.8)**
76,432 (30.4)**
2016
225,597
29,841 (13.2)**
35,560 (15.8)**
10,004 (4.4)**
4,168 (1.8)
215,240 (95.4)
1,144 (0.5)
173,829 (77.1)**
Total
1,078,653
197,004 (18.3)
35,560 (3.3)
10,470 (1.0)
5,158 (0.5)
863,595 (80.1)
2,064 (0.2)
250,261 (23.2)
Zambia
2013
96,183
37,310 (38.8)
NR (—)**
NR (—)**
NR (—)**
71,407 (74.2)
491 (0.7)
77,350 (80.4)
2014
154,941
65,481 (42.3)
NR (—)**
NR (—)**
0 (0.0)
116,881 (75.4)
1,742 (1.5)
130,360 (84.1)**
2015
147,962
52,716 (35.6)
82,197 (55.6)
12,701 (8.6)
4,533 (3.1)
125,137 (84.6)
2,429 (1.9)
134,762 (91.1)
2016
126,765
42,780 (33.7)
72,290 (57.0)
11,611 (9.2)
691 (0.5)
110,823 (87.4)
1,334 (1.2)
118,628 (93.6)
Total
525,851
198,287 (37.7)
154,487 (29.4)
24,312 (4.6)
5,224 (1.0)
424,248 (80.7)
5,996 (1.4)
461,100 (87.7)
Zimbabwe
2013
6,171
2,019 (32.7)
NR (—)**
NR (—)**
0 (0.0)
6,174 (100.0)
1 (<0.1)
NR (—)**
2014
39,840
14,827 (37.2)
NR (—)**
NR (—)**
1,085 (2.7)
39,837 (100.0)
135 (0.3)
36,566 (91.8)
2015
44,868
19,619 (43.7)
22,453 (50.0)
2,796 (6.2)
3,452 (7.7)
44,714 (99.7)
230 (0.5)
43,180 (96.2)
2016
57,282
24,784 (43.3)
27,065 (47.2)
5,433 (9.5)
12,648 (22.1)
57,136 (99.7)
726 (1.3)
54,772 (95.6)
Total
148,161
61,249 (41.3)
49,518 (33.4)
8,229 (5.6)
17,185 (11.6)
147,861 (99.8)
1,092 (0.7)
134,518 (94.7)
All countries
2013
983,542
312,015 (31.7)
NA
NA
1,319 (0.1)
737,844 (75.0)
9,166 (1.2)
226,389 (23.0)
2014
1,348,103
556,462 (41.3)
NA
NA
1,806 (0.1)
1,191,190 (88.4)
10,773 (0.9)
456,592 (33.9)
2015
1,355,020
489,814 (44.4)
537,722 (48.7)
63,770 (5.8)
15,438 (1.1)
1,158,745 (85.5)
14,644 (1.3)
909,515 (67.1)
2016
1,173,283
473,565 (47.0)
461,923 (45.8)
62,313 (6.2)
27,662 (2.4)
1,080,397 (92.1)
13,375 (1.2)
899,295 (76.6)
Total
4,859,948
1,831,856 (41.2)
999,645 (47.3)
126,083 (6.0)
46,225 (1.0)
4,168,176 (85.8)
47,958 (1.2)
2,491,791 (51.3)
Multi-country analyses** 2013
983,542
312,015 (31.7)
NA
NA
1,319 (0.2)
471,545 (83.6)
2,174 (0.9)
181,089 (64.8)
2014
1,348,103
556,462 (41.9)
NA
NA
1,806 (0.2)
853,389 (83.5)
4,574 (0.8)
321,660 (58.4)
2015
1,355,020
489,814 (44.4)
440,552 (48.4)
63,304 (7.0)
14,448 (1.3)
1,046,280 (94.8)
13,724 (1.3)
816,436 (75.7)
2016
1,173,283
439,475 (47.6)
353,441 (45.6)
50,895 (6.6)
24,947 (2.6)
923,970 (92.4)
7,032 (0.8)
578,669 (79.2)
Total 4,859,948 1,797,766 (41.5) 793,993 (47.1) 114,199 (6.8) 42,520 (1.1) 3,295,184 (89.3) 27,504 (1.0) 1,897,854 (71.9)

Abbreviations: NA = not applicable; NR = not reported; VMMC = voluntary medical male circumcision.

* October 1–September 30.

† Circumcision devices prequalified by the World Health Organization include the PrePex and ShangRing. However, PrePex was the predominant device in use in these 12 countries during 2013–2016.

§ HIV testing services exceeded 100% for certain countries that reported persons tested for HIV at VMMC clinics who did not undergo male circumcision.

¶ HIV prevalence was calculated by dividing the number of males that tested HIV positive by the number undergoing HIV testing services at VMMC sites.

** Excluded from multi-country analyses because the sum of values in the disaggregated indicator was <85% or >100% of the total number of VMMCs reported for the given year.

Abbreviation: VMMC = voluntary medical male circumcision. * October 1–September 30. Abbreviations: NA = not applicable; NR = not reported; VMMC = voluntary medical male circumcision. * October 1–September 30. † Circumcision devices prequalified by the World Health Organization include the PrePex and ShangRing. However, PrePex was the predominant device in use in these 12 countries during 2013–2016. § HIV testing services exceeded 100% for certain countries that reported persons tested for HIV at VMMC clinics who did not undergo male circumcision. HIV prevalence was calculated by dividing the number of males that tested HIV positive by the number undergoing HIV testing services at VMMC sites. ** Excluded from multi-country analyses because the sum of values in the disaggregated indicator was <85% or >100% of the total number of VMMCs reported for the given year. Data from multi-country analyses indicated that, during 2013–2016, 89.3% of VMMC clients participated in HIV testing services, and among those tested, the percentage of clients who tested positive ranged from 0.8% to 1.3% (at the country level, the percentage testing positive ranged from <0.1% to 4.4%) (Table 2). All VMMC clients were advised to return for a postoperative assessment; overall, 71.9% returned to the circumcising site within 14 days of surgery.

Discussion

During 2013–2016, nearly 5 million adolescent and adult males were medically circumcised by CDC-supported VMMC programs in 12 countries in Southern and Eastern Africa. Considering that a decade ago, male circumcision was not a social norm in many of these countries, and the human and structural resources for this surgical intervention were minimal before scale-up, this represents a substantial accomplishment. In addition, many of the men who sought VMMC would not have otherwise had contact with the medical system in the absence of significant injury or illness. However, the number of VMMCs declined in 2016, and several large-volume programs also performed fewer VMMCs in 2015. Multiple factors likely contributed to this decline, including 1) slowing of service delivery in several countries following recognition of tetanus as a rare but severe complication of VMMC, because many males in Southern and Eastern Africa were never fully immunized (); 2) retraining providers in dorsal slit circumcision technique in some countries upon identification that the forceps-guided technique posed elevated risk for injury to the immature penis (); 3) prioritization of VMMC service delivery to geographic regions with the highest HIV prevalence for greater impact; and 4) possibly declining demand because many early adopters had already been circumcised. Multiple countries increased the proportion of males aged 15–29 years who were provided VMMC in 2016, when PEPFAR began emphasizing prioritizing VMMC in this age group to most immediately achieve the HIV preventive benefit of VMMC (); however, the overall percentage of males aged 15–29 years who were circumcised declined in 2016. CDC continues to work with partners to identify and implement innovative approaches to increase VMMC demand among these men (). The large proportion of VMMC clients aged <15 years also likely accounts for the lower HIV prevalence observed among VMMC clients compared with national estimates,** because many of those aged <15 years likely had not yet had sexual intercourse, the primary mode of HIV transmission in this setting. The findings in this report are subject to at least four limitations. First, the findings reflect results from CDC-supported VMMC programs rather than national, PEPFAR, or global totals. Data entry errors and reporting variations are possible, and data were incomplete for some countries in some years. Second, during 2013–2014, the disaggregated age group indicator definition prevented reporting on males aged 15–29 years. Third, use of HIV testing services did not include clients with indeterminate results or those who might have been tested elsewhere recently, possibly affecting the HIV prevalence estimate among VMMC clients. Finally, follow-up within 14 days was likely underestimated because reported data might not include males who sought care at another health care site different from the one where they underwent circumcision. VMMC is an evidence-based, one-time intervention that confers lifelong partial protection against HIV infection for males. In addition, its benefits carry over to females by lowering the prevalence of HIV (and several other sexually transmitted infections) among potential sex partners (). To date, significant progress has been made by countries with VMMC programs. However, many more VMMCs need to be performed to reach the ambitious UNAIDS target by 2021. Enhancing VMMC service delivery will involve simultaneous focusing on supply-side and demand-side factors. On the supply side, VMMC programs are 1) offering service delivery on days and times that best match clients’ needs, including evening and weekend hours; 2) using mobile outreach service delivery to overcome geographic barriers; 3) ensuring safe service delivery through quality improvement and assurance activities and rigorous adverse event monitoring (); 4) where possible, layering VMMC service delivery with other health care services such as preexposure prophylaxis, HIV care and treatment, and general medical care; and 5) incorporating medical innovations (e.g., new circumcision devices) that might enhance acceptability of VMMC for some males. To increase demand for VMMC, programs are 1) evolving messaging from generating general awareness to addressing specific concerns of persons who have been hesitant to undergo VMMC; 2) linking VMMC with prevention activities for women (e.g., perinatal HIV testing services and HIV prevention programs that target adolescent girls and young women [i.e., the DREAMS program]); 3) engaging community stakeholders, such as traditional and religious leaders, celebrities, and satisfied VMMC clients, to become VMMC champions; 4) compensating clients for the opportunity cost of undergoing VMMC; and 5) ensuring VMMC services are available to men regardless of HIV status, through voluntarism of HIV testing services. Going forward, country programs at or nearing targets should begin planning for VMMC program sustainability, including VMMC training and program staffing operated by ministries of health, regional or national government contributions to VMMC financing, and establishing a framework to maintain high male circumcision coverage by continuing a VMMC program for adolescents males aged 10–14 years and/or introducing routine early infant male circumcision. Reaching and maintaining high male circumcision coverage in countries with high prevalence of HIV infection remains a critical component of achieving an AIDS-free generation.

What is already known about this topic?

Voluntary medical male circumcision (VMMC) has been recognized by the World Health Organization and Joint United Nations Programme on HIV/AIDS as an effective human immunodeficiency virus (HIV) infection prevention intervention in settings with a generalized HIV epidemic and low male circumcision prevalence. During 2010–2012, CDC (through the U.S. President’s Emergency Plan for AIDS Relief) supported 1,020,424 VMMCs in nine countries in Southern and Eastern Africa.

What is added by this report?

During 2013–2016, CDC-supported implementation partners performed 4,859,948 VMMCs in 12 countries in Southern and Eastern Africa, a substantial increase from 2010–2012.

What are the implications for public health practice?

Although millions of males have been medically circumcised in CDC-supported programs, many more VMMCs need to be performed to reach global targets. This will require redoubling current efforts and introducing novel strategies that increase demand among subgroups of males who have historically been reluctant to undergo VMMC.
  5 in total

Review 1.  Male circumcision for prevention of heterosexual acquisition of HIV in men.

Authors:  Nandi Siegfried; Martie Muller; Jonathan J Deeks; Jimmy Volmink
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

2.  Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.

Authors:  Jonathan M Grund; Carlos Toledo; Stephanie M Davis; Renee Ridzon; Edna Moturi; Heather Scobie; Boubker Naouri; Jason B Reed; Emmanuel Njeuhmeli; Anne G Thomas; Francis Ndwiga Benson; Martin W Sirengo; Leon Ngeruka Muyenzi; Gissenge J I Lija; John H Rogers; Salli Mwanasalli; Elijah Odoyo-June; Nafuna Wamai; Geoffrey Kabuye; James Exnobert Zulu; Jane Ruth Aceng; Naomi Bock
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-22       Impact factor: 17.586

3.  Age Targeting of Voluntary Medical Male Circumcision Programs Using the Decision Makers' Program Planning Toolkit (DMPPT) 2.0.

Authors:  Katharine Kripke; Marjorie Opuni; Melissa Schnure; Sema Sgaier; Delivette Castor; Jason Reed; Emmanuel Njeuhmeli; John Stover
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

4.  Increasing voluntary medical male circumcision uptake among adult men in Tanzania.

Authors:  Mwita Wambura; Hally Mahler; Jonathan M Grund; Natasha Larke; Gerry Mshana; Evodius Kuringe; Marya Plotkin; Gissenge Lija; Maende Makokha; Fern Terris-Prestholt; Richard J Hayes; John Changalucha; Helen A Weiss
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

5.  Voluntary medical male circumcision - southern and eastern Africa, 2010-2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-29       Impact factor: 17.586

  5 in total
  11 in total

1.  Barriers, benefits, and behaviour: Voluntary medical male circumcision ideation in a population-based sample of Zambian men.

Authors:  Joseph G Rosen; Maria A Carrasco; Ariana M Traub; E 'Kuor Kumoji
Journal:  Afr J AIDS Res       Date:  2021-12       Impact factor: 1.300

Review 2.  Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Authors:  Linda-Gail Bekker; George Alleyne; Stefan Baral; Javier Cepeda; Demetre Daskalakis; David Dowdy; Mark Dybul; Serge Eholie; Kene Esom; Geoff Garnett; Anna Grimsrud; James Hakim; Diane Havlir; Michael T Isbell; Leigh Johnson; Adeeba Kamarulzaman; Parastu Kasaie; Michel Kazatchkine; Nduku Kilonzo; Michael Klag; Marina Klein; Sharon R Lewin; Chewe Luo; Keletso Makofane; Natasha K Martin; Kenneth Mayer; Gregorio Millett; Ntobeko Ntusi; Loyce Pace; Carey Pike; Peter Piot; Anton Pozniak; Thomas C Quinn; Jurgen Rockstroh; Jirair Ratevosian; Owen Ryan; Serra Sippel; Bruno Spire; Agnes Soucat; Ann Starrs; Steffanie A Strathdee; Nicholas Thomson; Stefano Vella; Mauro Schechter; Peter Vickerman; Brian Weir; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

3.  Consent Challenges and Psychosocial Distress in the Scale-up of Voluntary Medical Male Circumcision Among Adolescents in Western Kenya.

Authors:  Winnie K Luseno; Samuel H Field; Bonita J Iritani; Stuart Rennie; Adam Gilbertson; Fredrick S Odongo; Daniel Kwaro; Barrack Ongili; Denise D Hallfors
Journal:  AIDS Behav       Date:  2019-12

4.  Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data.

Authors:  Tanwei Yuan; Thomas Fitzpatrick; Nai-Ying Ko; Yong Cai; Yingqing Chen; Jin Zhao; Linghua Li; Junjie Xu; Jing Gu; Jinghua Li; Chun Hao; Zhengrong Yang; Weiping Cai; Chien-Yu Cheng; Zhenzhou Luo; Kechun Zhang; Guohui Wu; Xiaojun Meng; Andrew E Grulich; Yuantao Hao; Huachun Zou
Journal:  Lancet Glob Health       Date:  2019-04       Impact factor: 26.763

5.  Ethics of pursuing targets in public health: the case of voluntary medical male circumcision for HIV-prevention programs in Kenya.

Authors:  Stuart Rennie; Adam Gilbertson; Denise Hallfors; Winnie K Luseno
Journal:  J Med Ethics       Date:  2020-11-04       Impact factor: 2.903

6.  Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial.

Authors:  Kathleen E Wirth; Tendani Gaolathe; Molly Pretorius Holme; Mompati Mmalane; Etienne Kadima; Unoda Chakalisa; Kutlo Manyake; Atang Matildah Mbikiwa; Selebaleng V Simon; Rona Letlhogile; Kutlwano Mukokomani; Erik van Widenfelt; Sikhulile Moyo; Kara Bennett; Jean Leidner; Kathleen M Powis; Refeletswe Lebelonyane; Mary Grace Alwano; Joseph Jarvis; Scott L Dryden-Peterson; Coulson Kgathi; Janet Moore; Pam Bachanas; Elliot Raizes; William Abrams; Lisa Block; Baraedi Sento; Vlad Novitsky; Shenaaz El-Halabi; Tafireyi Marukutira; Lisa A Mills; Connie Sexton; Sherri Pals; Roger L Shapiro; Rui Wang; Quanhong Lei; Victor DeGruttola; Joseph Makhema; Myron Essex; Shahin Lockman; Eric J Tchetgen Tchetgen
Journal:  Lancet HIV       Date:  2020-06       Impact factor: 16.070

Review 7.  Adolescent lives matter: preventing HIV in adolescents.

Authors:  Audrey Pettifor; Marie Stoner; Carey Pike; Linda-Gail Bekker
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

8.  Voluntary medical male circumcision for HIV prevention among adolescents in Kenya: Unintended consequences of pursuing service-delivery targets.

Authors:  Adam Gilbertson; Barrack Ongili; Frederick S Odongo; Denise D Hallfors; Stuart Rennie; Daniel Kwaro; Winnie K Luseno
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

9.  Prevalence of Voluntary Medical Male Circumcision for HIV Infection Prevention - Chókwè District, Mozambique, 2014-2019.

Authors:  Jonas Z Hines; Ricardo Thompson; Carlos Toledo; Robert Nelson; Isabelle Casavant; Sherri Pals; Marcos Canda; Juvencio Bonzela; Alicia Jaramillo; Judite Cardoso; Dawud Ujamaa; Stelio Tamele; Victor Chivurre; Inacio Malimane; Ishani Pathmanathan; Kristen Heitzinger; Stanley Wei; Aleny Couto; Jotamo Come; Alfredo Vergara; Duncan MacKellar
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-07-02       Impact factor: 17.586

10.  Sexual function after voluntary medical male circumcision for human immunodeficiency virus prevention: Results from a programmatic delivery setting in Botswana.

Authors:  Jillian C Pintye; Kathleen E Wirth; Conrad Ntsuape; Nora J Kleinman; Lisa Spees; Bazghina-Werq Semo; Shreshth Mawandia; Jenny Ledikwe
Journal:  South Afr J HIV Med       Date:  2020-04-20       Impact factor: 2.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.